A mesoporous polydopamine nanoparticle enables highly efficient manganese encapsulation for enhanced MRI-guided photothermal therapy

Wu, Yan; Huang, Yu; Tu, Chunlai; Wu, Fengren; Tong, Gangsheng; Su, Yue; Xu, Li; Zhang, Xiaoqin; Xiong, Shuqiang; Zhu, Xinyuan

doi:10.1039/d1nr00957e

Cited by 25 publications

(10 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To overcome this limitation, manganese is a good substitute because of its inherent advantages, such as low intrinsic toxicity and effective positive contrast enhancement effect [ 117 , 118 ]. Wu et al [ 119 ] synthesized MPDA NPs (called MPDAPs) using the soft template method and then complexed Mn 2+ to obtain MPDAPs/Mn. In vitro infrared imaging analysis revealed that the photothermal conversion efficiency of MPDAPs/Mn was as high as 45.2%.…”

Section: Cancer Theranosticsmentioning

confidence: 99%

Recent developments in mesoporous polydopamine-derived nanoplatforms for cancer theranostics

et al. 2021

View full text Add to dashboard Cite

Polydopamine (PDA), which is derived from marine mussels, has excellent potential in early diagnosis of diseases and targeted drug delivery owing to its good biocompatibility, biodegradability, and photothermal conversion. However, when used as a solid nanoparticle, the application of traditional PDA is restricted because of the low drug-loading and encapsulation efficiencies of hydrophobic drugs. Nevertheless, the emergence of mesoporous materials broaden our horizon. Mesoporous polydopamine (MPDA) has the characteristics of a porous structure, simple preparation process, low cost, high specific surface area, high light-to-heat conversion efficiency, and excellent biocompatibility, and therefore has gained considerable interest. This review provides an overview of the preparation methods and the latest applications of MPDA-based nanodrug delivery systems (chemotherapy combined with radiotherapy, photothermal therapy combined with chemotherapy, photothermal therapy combined with immunotherapy, photothermal therapy combined with photodynamic/chemodynamic therapy, and cancer theranostics). This review is expected to shed light on the multi-strategy antitumor therapy applications of MPDA-based nanodrug delivery systems. Graphical Abstract

show abstract

Section: Cancer Theranosticsmentioning

confidence: 99%

Recent developments in mesoporous polydopamine-derived nanoplatforms for cancer theranostics

et al. 2021

View full text Add to dashboard Cite

show abstract

“…According to their result, the tumor ablation could be observed after MPDA-PEG-PTX treatment combined with 2 Wcm-2 laser irradiations for 5 min. In addition to chemo-photothermal therapy, MPDA could also be applied to immuno-photothermal, a combination of photothermal therapy and photodynamic therapy/chemodynamic therapy, as well as cancer theranostics ( Hu et al, 2019 ; Huang et al, 2021 ; Wu et al, 2021 ). However, few studies have illustrated the potential toxicity of MPDA so far, which blocked further clinical application.…”

Section: Discussionmentioning

confidence: 99%

RNA-Seq Based Toxicity Analysis of Mesoporous Polydopamine Nanoparticles in Mice Following Different Exposure Routes

Huang

Xie

Zhang

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Mesoporous polydopamine nanoparticles (MPDA NPs) are promising nanomaterials that have the prospect of clinical application for multi-strategy antitumor therapy, while the biosecurity of MPDA NPs remains indistinct. Here, transcriptome sequencing (RNA-Seq) was performed to systematically reveal the toxicity of MPDA NPs to five categories of organs after three different exposure routes, including intravenous injection, intramuscular injection, and intragastric administration. Our results uncovered that MPDA NPs could be deposited in various organs in small amounts after intravenous administration, not for the other two exposure routes. The number of differentially expressed genes (DEGs) identified in the heart, liver, spleen, lung, and kidney from the intragastric administration group was from 22 to 519. Similarly, the corresponding number was from 23 to 64 for the intramuscular injection group and was from 11 to 153 for the intravenous injection group. Functional enrichment analyses showed 6, 39, and 4 GO terms enriched for DEGs in intragastric administration, intramuscular injection, and intravenous injection groups, respectively. One enriched pathway was revealed in intragastric administration group, while no enriched pathway was found in other groups. Our results indicated that MPDA NPs produced only slight changes at the transcriptome level in mice, which provided new insights for further clinical application of MPDA NPs.

show abstract

“…The therapeutic process could be monitored by T 2 ‐weighted MRI and an infrared thermal camera. More recently, polydopamine‐coated mesoporous silica particles loaded with manganese ions were proven to be potent T 1 MRI CAs and photosensitizing agents with excellent PTCE in an in vivo mice model 79 . Beik and coworker established a computational model to simulate the heat transfer process in the tumor during PTT, based on MRI data and nanoparticle distribution in vivo.…”

Section: Theranostics For Mri‐guided Thermal Therapymentioning

confidence: 99%

Theranostics for MRI‐guided therapy: Recent developments

Zhang

Zhou

Davies

et al. 2021

VIEW

View full text Add to dashboard Cite

Recent advances in bioimaging, biochemistry, and bioinformatics have facilitated the development of personalized and precision medicine. Theranostics, combining imaging modalities and therapeutic agents, have garnered a lot of attention in this context, owing to their potential to monitor and control treatment for individual patients. A promising strategy to achieve this goal involves the development of therapy guided by magnetic resonance imaging (MRI). MRI has a high degree of soft tissue contrast, low invasiveness, high depth of penetration and good spatial resolution. MRI‐guided therapy could thus allow precise and time‐resolved assessment of disease conditions and therapeutic progression. This article will give a brief introduction to the principles of MRI, and describe recently developed strategies to produce MRI‐guided therapies. A number of theranostics based on T1, T2, or chemical exchange saturation transfer (CEST) MRI have been explored to track the route of drug carriers in vivo and image diseased tissue so as to enhance bioavailability, overcome complex delivery barriers, and assess therapeutic responses. In addition, the integration of thermal therapy and MRI imaging offers a strategy to noninvasively identify target areas, plan treatment, and provide real‐time assessment of the efficacy of tumor ablation. We also discuss advances in intelligent nanoparticles combining small molecule drugs, thermal treatment and multimodal imaging, arguing that these multifunctional agents can further improve therapeutic outcomes.

show abstract

A mesoporous polydopamine nanoparticle enables highly efficient manganese encapsulation for enhanced MRI-guided photothermal therapy

Abstract: Theranostic agents based on magnetic resonance imaging (MRI) and photothermal therapy (PTT) play an important role in tumor therapy. However, available theranostic agents are confronting great challenges in the issues...

Cited by 25 publications

References 52 publications

Recent developments in mesoporous polydopamine-derived nanoplatforms for cancer theranostics

Recent developments in mesoporous polydopamine-derived nanoplatforms for cancer theranostics

RNA-Seq Based Toxicity Analysis of Mesoporous Polydopamine Nanoparticles in Mice Following Different Exposure Routes

Theranostics for MRI‐guided therapy: Recent developments

Contact Info

Product

Resources

About